Photo taken from CCTG/X
Aug 12, 2024, 01:27
Michael Ong received $2.4M for metastatic prostate cancer – CCTG
The Canadian Cancer Trials Group shared on X:
“Congratulations to Dr Michael Ong, who has received $2,487,015 over 7 years from CIHR to support the CCTG PR26 (TRIPLE-SWITCH) trial. The study aims to personalize chemotherapy use and improve survival for patients with metastatic prostate cancer.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 23, 2025, 02:12
Feb 23, 2025, 02:08
Feb 23, 2025, 01:54
Feb 23, 2025, 01:46
Feb 23, 2025, 01:42
Feb 23, 2025, 01:28